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Introduction
Pelvic girdle pain (PGP) occurs in 70% of pregnant women; of 
whom 25% have severe pain and 8% severe disability requiring the 
use of crutches, wheelchair or confinement to bed [1]. Patients with 
pregnancy related PGP have been shown to have increased pelvic 
joint motion compared with healthy pregnant controls, probably due 
to a combination of hormonal and biomechanical factors, leading 
to an increase in pelvic joint laxity, changes in lumbopelvic posture 
and increase in shearing forces through pelvic joints, thus leading to 
pain [2,3]. PGP is difficult to manage; activities such as turning in 
bed, prolonged walking, or carrying items may cause pain; impacting 
negatively on quality of life [4]. In economic terms societal costs 
are significant, mainly as a consequence of work absenteeism; with 
20% of people requiring an average of 7-11 weeks sick leave [5-8]. 
There are high direct health costs as well as increased health risks 
as women with PGP have a higher request for induction of labour 
and elective caesarean section to achieve symptomatic relief [3,5,7].
Orthoses such as pelvic belts are commonly used in clinical practice 
to manage pregnancy related PGP [9,10]. They are used to apply 
external compression to the pelvis to improve pelvic stability, increase 
neuromuscular control and reduce shearing forces through the pelvis, 
by way of a substitute for reduced ‘force closure’ associated with 
pelvic pain [9]. Studies, for example, suggest that the orthoses may 
be effective in reducing sacro-iliac joint (SIJ) laxity and provide 
more effective load transfer through the pelvis [11,12]. Recently, 
dynamic elastomeric fabric orthoses (DEFO’s) have been developed 
for PGP management. Evidence of their effectiveness in reducing 
pain and improving function is, however, limited to athletes and two 
case reports in pregnant women, providing preliminary evidence of 
benefits in terms of pain, function and comfort [13]. The purpose of 
this study was to investigate the relative effectiveness of this newly 
developed orthosis compared to other commercially available pelvic 
belts in managing pregnancy related PGP.
Our primary aim was to determine the relative effectiveness of 
a rigid pelvic orthosis (plus standardised advice) compared to a 
customised DEFO (plus standardised advice) in reducing pain in 
pregnant women with PGP. Secondary aims were to compare these 
two interventions in terms of activity levels and health-related 
quality of life.
Materials and Methods
Ethical approval was gained from the National Research Ethics 
Service, South West 3 Regional Ethics Committee (REC reference 
number: 12/SW/0014), and the Faculty of Health Ethics Committee 
at Plymouth University. National Health Service (NHS) Research 
and Development approval was gained from the participating NHS 
centre.
Trial Design
This was a single centred, double blinded, randomised comparative 
trial (RCT). CONSORT guidelines were adhered to maintain a 
quality and transparent approach [14]. Fig 1 shows the CONSORT 
flow chart detailing participant flow through the trial.
Figure 1: Consort Flow chart
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Setting and Participants
The trial was carried out within the maternity department of a 
regional hospital in the South West of England, United Kingdom. 
Recruitment commenced in January 2013 and ceased in December 
2014 due to reaching recruitment target.
Participants were recruited from the maternity department of the 
regional hospital. The Consultant Obstetricians and Midwives were 
the main recruiters as they typically had first contact with women 
with pregnancy related musculoskeletal problems. With the potential
participant’s consent, the lead researcher was informed, via a generic 
email account/ contact telephone number, of the individual’s contact 
details. This enabled them to contact the participant, typically 
within 24 hours, to investigate whether it was appropriate to book 
a screening appointment with the individual to determine their 
eligibility for inclusion within the trial.
To be eligible for entry to the trial participants were required to have 
intermittent PGP (commenced during or aggravated by pregnancy), 
which caused walking and/or stairs to be bothersome and were 
between 20 and 36 weeks pregnant. The decision was taken to 
not enrol any participants before 20 weeks due to the potential for 
increased complication rate within the 1st Trimester and no later 
than 36 weeks due to the practicality of providing a custom made 
orthosis so close to their delivery date. The participant also had to 
test positive on at least three out of seven pain provocation tests (one 
out of two symphysis pain tests and two of the five SIJ pain tests 
as detailed under the classification of pelvic girdle pain (see Fig 2).
Figure 2: The pain provocation pathway required for inclusion or exclusion of the study
Exclusion criteria were a reported history or signs and symptoms 
indicative of a serious cause of pain that might be inflammatory, 
infective, traumatic, neo plastic, degenerative or metabolic. This 
included a history of trauma, unexplained weight loss, history of 
cancer, steroid use, drug abuse, HIV infection, immune suppressed 
state, neurological symptoms such as bowel or bladder, sensory, 
motor, reflex involvement (cauda equina, lumbar disc lesion, spinal 
stenosis), fever, systemically unwell, obstetric complications, pain 
that does not improve with rest/severe disabling pain. Also excluded 
were those women with a history of chronic back or pelvic pain 
requiring surgery, focal inflammatory signs/tenderness of the spine 
(spondylolisthesis), those who had a known allergy to Lycra, or 
were<20 or > 36 weeks pregnant.
Screening
Having confirmed the participant wished to take part in the study 
their written informed consent was obtained for the screening 
appointment, which was held at the regional hospital. This was 
undertaken by the lead physiotherapy researcher (LC), in the 
presence of a female chaperone. Screening involved:
• Gathering demographic and diagnostic information to confirm 
eligibility criteria, described above
• Identifying pain sites using a Pain Referral Map3
• Undertaking a pain provocation test battery for diagnosis of 
pelvic girdle pain. The tests used were those recommended by 
the European Guidelines for the diagnosis and management of 
pelvic girdle pain [3](Fig 2)
Symphysis Pain: Palpation of the symphysis or Modified 
Trendelenburg test
Sacroiliac Joint (SIJ) Pain: Posterior pelvic pain provocation test 
(P4/thigh thrust), Patrick’s Faber Test and Gaenslen’s test.
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All tests were undertaken in a standardised order to enable 
confirmation of eligibility, whilst minimising aggravation of pain 
irritability. The order of tests was as follows (Fig 2): The Modified 
Trendelenburg test was undertaken first to identify pain in the SP. 
If this test was positive, SIJ tests were then carried out. If it was 
negative direct palpation of symphysis was undertaken, if this test 
was negative then the female was excluded from the trial, if it was 
positive then SIJ tests were undertaken. For SIJ pain tests, the P4 
test was applied first (bilaterally), followed by the Patrick’s Faber 
test (bilaterally), and Gaenslan’s test. If two of the SIJ tests were 
positive then the female was recruited into the study. If not testing 
continued to the final SIJ provocation test, Gaensléns test, The tests 
were ranked in this hierarchy based on their provocation levels and 
the positions the participants would have to get into for testing.
Randomisation and Blinding
To optimise blinding, all participants who met the inclusion criteria 
were measured for a customised DEFO at the conclusion of the 
screening process, regardless as to whether or not they were randomly 
allocated to receive this intervention. The measurement process, 
which involved undertaking 12-13 pre-specified measurements, 
was undertaken by the physiotherapy researcher (LC) with the 
assistance of a female chaperone, and took approximately six 
minutes to complete. This ensured that all participants were given 
the same amount of time and attention, regardless of potential group 
allocation.
Following screening and confirmation of eligibility, participants were 
asked to leave the room whilst they were randomly allocated, by the 
method of minimisation. This has been referred to as the platinum 
standard for randomised trials [15]. Participants were allocated to
receive either the off-the-shelf rigid pelvic belt plus standardised 
advice or the customised DEFO plus standardised advice. In line 
with recommendations by Scott (2002), the first 10 participants were 
randomised through the use of a randomised number generator (http
http://www.random.org/) to limit bias [16]. Thereafter, computer 
software ‘minim’ (https://www-users.york.ac.uk/~mb55/guide/
minim.htm) was used by the lead researcher (LC) to allocate 
participants to either group according to: age, gestation, parity and 
body mass index, since these variables have demonstrated to be 
prognostic indicators for PGP [16]. The software accommodated 
these variables and balanced the group selection accordingly, 
ensuring a more even distribution of potential factors which could 
alter any intervention effect.
Following randomisation, all participants were given an appointment 
seven days later in order to undertake the baseline assessments 
and receive the allocated intervention. This seven-day time frame 
allowed for the production of the customised DEFO and ensured that
the timeline and experience of both groups were matched.
Interventions
In line with TIDieR Guidelines, full details of each intervention are 
described below [17].
Standardised Advice
In addition to the orthoses, participants in both Groups were given 
the same standardised advice sheet ‘Guidance for mothers to be and 
new mothers: Pregnancy-related pelvic girdle pain’ accessible via 
the Association of Chartered Physiotherapists in Women’s Health
website (http://www.csp.org.uk/sites/files/csp/secure/acpwh-
pgppat_0.pdf). The participant could use this as a resource throughout 
their pregnancy. All the participants were also given a standard 
advice sheet regarding the washing of their orthosis.
Off-the-shelf rigid pelvic belt
This pelvic belt (supplied by Serola Biomechanics Inc. www.
appliedbiomechanics.co.uk/) consisted of an open cell urethane 
inner layer (3” in width), wrapping the circumference of the pelvic 
girdle and fastening with Velcro tape (see Fig 3). It has an added 
extra-strong, double-pull elastic straps which can be applied, also 
with Velcro tape, for further tension and support. The Serola Belt 
required a single waist measurement.
Figure 3: Shows both interventions: the Serola belt (Top) and the 
customised dynamic elastomeric orthoses (DEFO) (Bottom).
Customised Dynamic Elastomeric Fabric Orthosis (DEFO)
A customised Dynamic Elastomeric Fabric Orthosis (DEFO) 
(supplied by DM Orthotics’ Ltd, www.dmorthotics.com/) was 
supplied and fitted by the lead physiotherapy researcher (LC)(see 
Fig 3). This orthosis was individually tailored to the participant on 
the basis of 12 measurements for the 2nd trimester participants (13-27 
weeks pregnant) and 13 measurements for 3rd trimester participants 
(28-40 weeks pregnant). Designed in the form of a pair of shorts 
opposed to the standard belt, the customised DEFO is made of a 
flexible compression fabric (Lycra) to aid pelvic stability, providing 
comfort and movement. It has reinforced panelling for strength and 
stability with an option for open crotch available (a closed crotch 
was used during this study).
Data Collection Procedures
At the day seven appointment, participants completed their first 
battery of self-report questionnaires (described below) in the waiting 
room before contact with the lead researcher (to maintain lead 
researcher blinding). The completed questionnaires were placed into 
a sealed, opaque, freepost envelope and posted to an independent 
researcher at the University. At the same time they were also supplied 
with folders containing questionnaires and freepost envelopes 
grouped together in two week batches. They were requested to 
return the completed questionnaires to the independent external 
blinded researcher every two weeks. Each envelope was given a 
unique code so that the independent external blinded researcher 
could systematically check that the forms had been returned and 
fully completed. A notification system was in place to follow up 
any non-returns or missing data by telephone. At this telephone 
conversation the question (pertaining to the missing data) was read 
out and the participant was requested to provide a response. This 
telephone conversation was scripted to ensure standardisation. Once 
checked the questionnaire was locked in a cabinet which only the 
independent external blinded researcher could access. Blinding of 
the lead researcher, and other members of the research team, was 
thereby ensured for the duration of the study.
Outcome Measures
Standardised, validated self-report postal questionnaires were 
compiled in a questionnaire booklet. Participants were requested 
to complete the booklet in the pre-designed order; this typically took 
approximately 10 minutes. Some answers required extra information 
if answered ‘yes’ or ‘no’ so that, at a minimum, participants were 
asked to answer 79 items, and at a maximum 88 items.
The primary outcome measure was the Numerical Pain Rating Scale 
(NPRS), which is the gold standard for reporting pain intensity within 
healthcare, with established validity and reliability [18-20]. This 
11-point scale, consists of  integers from 0 (no pain) to 10 (unbearable 
pain). In this study pain intensity was measured by asking two 
questions: (1) “Over the last week, how would you rate your average 
level of pelvic pain during the day?” and (2) “Over the last week, how 
would you rate your average level of pelvic pain during the night (after 
going to bed)?” Pain classifications were divided between mild pain 
(0-4), moderate pain (5-7) and severe pain (8-10) [18-21].
The secondary outcome measures were the:
• Pelvic Girdle Questionnaire (PGQ); this condition-specific, 25-
item self-report questionnaire evaluates activity/participation 
(20 items) and body functions/symptoms (5 items) (5) using 
a 4-point Likert scale. High validity and reliability have been 
reported by the developer, however more research is required 
to further support this claim [22,23].
• European Quality of Life 5 Dimension, 5 level Questionnaire 
(EQ5D-L): this widely used, generic, 5-item self-report 
questionnaire with established psychometric properties provides 
an evaluation of health related quality of life (HRQoL) and 
a standardised health index to enable cost utility or cost 
effectiveness analysis [24-26].
• Short Form-36 Version 2 (SF-36v2): this 36 item self-report 
questionnaire is widely viewed as the gold standard generic 
health related quality of life measure with evidence to support 
its use in pregnant women. This version asks participants to 
rate their quality of life over the past week [27-29].
Sample Size
The recruitment target of 72 was based on data from Depledge RCT 
which assessed effectiveness of pelvic belts and exercise on PGP 
in pregnant women [30]. Average pain (measured by VAS) was 
assessed before and after a one week intervention. A combination of
a non-rigid belt and exercise decreased pain from 42.5% (±11 mean 
±SD) to 38.5% (±11) whilst a rigid belt and exercise decreased pain 
from 52 % (±11) to 38.5% (± 11).The resultant effect size was 0.86 
[(42.5-38.5)-(52-38.5) / 11]. For a two tailed unpaired t-test at 85%
power and a significance level of 0.05 an estimated 25 people were 
required in each group. Depledge et al’s attrition rate was 6.6% for 
two outcome measures spaced one week a part; attrition rates of up to 
20% have been reported in other studies [30]. With an estimated 10%
attrition rate for each measurement session (n=4) we aimed to recruit 
36 participants in each group.
Data Analysis
Due to a variable baseline length, as a result of participants entering 
the trial at different time points relative to their delivery date, the 
analyses of outcome measures were calculated using the final three 
time points pre partum (antenatal -6 /-4 /-2 weeks) and the first three 
time points post-partum (postnatal +2/+4/+6 weeks).
Separate analyses were performed for each of the outcome measures 
using SPSS Software (IBM Corp. Released 2013. IBM SPSS 
Statistics for Windows, Version 22.0. Armonk, NY) and Quality 
Metric Outcomes TM Scoring Software 4.5 to score the SF-36v2. 
Separate 2x3 (Group x Time) repeated measure analysis of variance 
(RM-ANOVA), were used to analyse the NPRS and the EQ5D-L 
dimensions and EQ5DL- VAS pre and postpartum. A Mann- Whitney 
U test was used for analysis of the SF36 to compare group differences 
and Freidman’s test to compare differences between time intervals. 
A Mann-Whitney U test was used for analysis of the PGQ and the 
EQ5D-5L subscales.For all tests, the alpha level was set at .05 
and Bonferroni corrections were used when post hoc pair wise 
comparisons were calculated.
The primary outcome measure, NPRS, was assessed for clinical 
significance using a Minimal Clinically Important Difference 
(MCID) of one point [31]. The mean difference from the final pre-
pregnancy data point (-2 weeks) was compared against baseline in 
both the groups to identify any reduction in pain score.
Results
Table 1 details the sample characteristics. There was complete 
data for all participants for all time points. Table 2 details mean 
and standard deviations for both primary and secondary outcome 
measures for both the SEROLA and DEFO group.
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Table 1. Sample characteristics
Participant Characteristics
(n=72) SEROLA (n=36) DEFO (n=36)
Age 29 (18-39) 30 (20-40)
Gestation 29 (20-35) 28 (20-35)
Parity 1.3 (0-3) 1.4 (0-3)
SEROLA = off-the-shelf rigid orthosis; DEFO = customised Dynamic Elastomeric Fabric Orthosis
Table 2: Descriptive statistics for all outcome measures across time and allocated to groups (SEROLA and DEFO)
SEROLA (Antenatal) SEROLA (Postnatal) DEFO (Antenatal) DEFO (Postnatal)
Time in weeks relative to birth
Antenatal = -6/-4/-2 & Postnatal = +2/+4/+6
Outcome Measures
(Mean(+/- SD))
Baseline
scores
-6 -4 -2 +2 +4 +6 Baseline
scores
-6 -4 -2 +2 +4 +6
NPRS DAY *
Available range 0-10
6.00
(1.20)
5.56
(1.59)
5.72
(1.65)
5.92
(1.65)
1.36
(1.07)
1.06
(0.92)
0.83
(0.91)
5.92
(1.42)
4.89
(1.83)
5.03
(1.76)
4.92
(1.86)
1.06
(1.51)
1.06
(1.96)
1.00
(2.00)
NPRS NIGHT *
Available range 0-10
6.61
(1.75)
6.22
(1.94)
5.92
(1.79)
5.97
(2.04)
1.39
(1.27)
1.19
(1.06)
0.94
(1.07)
5.78
(2.17)
5.06
(2.33)
5.22
(2.19)
4.83
(2.30)
1.11
(1.19)
1.14
(2.02)
1.06
(2.10)
PGQ †
Available range
 0-100
64.78
(12.64)
61.9
(16.61)
62.3
(17.42)
64.8
(19.12)
16.9
(13.41)
12.2
(10.95)
10.1
(10.31)
64.19
(11.91)
62.2
(18.80)
61.4
(20.28)
62.0
(20.98)
14.1
(13.08)
14.8
(19.62)
12.1
(19.60)
EQ5D‡
Available range 0-10
0.52
(0.17)
0.51
(0.22)
0.51
(0.17)
0.47
(0.17)
0.74
(0.11)
0.78
(0.12)
0.81
(0.12)
0.49
(0.20)
0.48
(0.19
0.52
(0.17)
0.47
(0.20)
0.77
(0.13)
0.78
(0.23)
0.81
(0.23)
EQ5D VAS§
Available range
 0-100
55.69
(17.33)
54.89
(16.68)
52.22
(17.09)
50.56
(16.36)
74.36
(13.13)
74.39
(13.83)
77.50
(14.16)
60.89
(17.17)
58.33
(20.24)
57.61
(18.39)
55.64
(18.47)
70.50
(18.57)
74.86
(20.18)
77.44
(19.37)
SF36 (PC)||
Available range 
0-100
35.51
(7.30)
34.91
(7.46)
34.91
(7.64)
33.12
(7.98)
45.37
(7.94)
48.27
(7.78)
50.60
(7.90)
35.62
(5.95)
34.26
(5.72)
34.78
(6.37)
35.09
(6.61)
46.16
(7.00)
47.82
(9.24)
51.86
(9.06)
SF36 (MC)¶
Available range 
0-100
43.61
(9.46)
43.75
(11.02)
42.84
 (11.45)
41.98
(10.41)
49.34
(9.07)
51.27
(8.97)
50.86
(9.13)
46.77
(9.90)
47.85
(11.29)
48.16
(10.62)
48.52
(10.54)
55.08
(9.77)
56.65
(10.64)
56.03
(9.44)
* Numerical Patient Reported Score (NPRS) primary outcome measure - higher scores = worse pain; negative change score = improvement
† Pelvic Girdle Questionnaire (PGQ) Secondary outcome measure – higher scores = more pain during tasks; positive change score =
improvement
‡EuroQol 5 dimension (EQ5D) secondary outcome measure higher scores = worse quality life; positive change score = improvement
§EuroQol 5 dimension Visual Analogue Scale (EQ5D – VAS) secondary outcome measure lower scores = worse quality of life; negative
change score = improvement
|| Short Form 36 item questionnaire – physical component (SF36 (PC)) secondary outcome measure Low scores = worse quality of 
life; positive change score = improvement
¶ Short Form 36 item questionnaire – mental health component (SF36 (MC)) secondary outcome measure. Low scores = worse quality 
of life; change score = improvement
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Primary Outcome Measure
Numerical Pain Rating Scale – DAY (NPRS-DAY):
The antenatal data analyses revealed no significant main effect of 
Time F(2, 14) = .901, p =.409, but a significant difference between 
the groups F(1, 70) = 4.601, p<.05. There was no interaction between 
time and groups F(2, 140) = 2.079, p = .129. Pair wise comparisons
revealed a significant difference between the two groups at the final 
(-2 week) antenatal time point (p <.05), while the second (-4 week) 
time point approached significance (p = .089) with the SEROLA 
group ranking consistently higher day pain ratings (i.e. worse pain) 
than the DEFO group (see Fig 4 and 5).
Analysis of the postnatal data revealed no significant main effect of 
Time F(2, 140) = 3.085, p =.063, or significant differences between 
Groups, F(1, 70) = .021, p = .885, indicating similar postnatal scores 
for the two groups across time. Pair wise comparisons revealed a
significant decrease in pain ratings for the SEROLA group from 
the first and last (+2 to +6) postnatal time points (p< .05), but no 
significant change across Time for the DEFO group (p>.05), and 
no significant differences between Groups at all time points (p<.05) 
(Fig 4 and 5).
Figure 4: Mean day NPRS for SEROLA  and DEFO groups at 
pre-birth time points (-6, -4, -2 weeks) and post-birth time points 
(+2, +4, +6 weeks). Vertical dotted line symbolises birth of child
Figure 5: Grand average day NPRS for SEROLA and DEFO groups 
over the pre and post birth periods, along with 95% confidence 
intervals
The analysis of minimally clinical important difference (MCID) 
was significant in the DEFO group with a one point reduction in the 
NPRS (Baseline = 5.917; Final pre-pregnancy data point = 4.917 
(-2)). There was no MCID found for the Serola group.
Numerical Pain Rating Scale – Night (NPRS-NIGHT)
The antenatal data analyses revealed a similar pattern of results to 
the day NPRS with no significant effect of Time F(2, 140) = 1.233, p 
=.297, but a significant difference between Groups, F(1, 70) = 4.657, 
p<.05, and no significant interaction between time and groups. Pair
wise comparisons revealed a significant difference between the 
groups at both the first (-6) and final (-2) prenatal time points (p’s 
<.05), indicating significantly higher night pain ratings (worse pain) 
for the SEROLA group compared to the DEFO group. Furthermore, 
a decrease in pain ratings for the DEFO group from time points -4 
to -2 approached significance (p =.053), while pain ratings for the 
SEROLA group increased, but not significantly (p = .779) (see Fig 
6 and 7).
Figure 6: Mean night NPRS data for both  SEROLA  and DEFO, 
at pre-birth time points (-6, -4, -2) and post-birth time points (+2, 
+4, +6), dotted line symbolises birth of child.
Figure 7: Total mean data for both SEROLA and DEFO, at pre and 
post birth, along with upper and lower 95% confidence intervals
Analysis of the postnatal data revealed no significant main effect of 
Time F(2, 140) = 2.104, p =.142, or significant differences between 
Groups, F(1, 70) = .051, p =.821. Pair wise comparisons revealed no 
significant differences between the groups at all time points (all p’s
>.05), and a significant decrease in pain ratings for the SEROLA 
groups from +4 to +6 time points (p<.05), but no significant change 
for the DEFO group (p =.410)(Fig 6 and 7).
There was no MCID found for either the Serola or DEFO, although 
both groups reported a reduction in pain. However, the mean 
difference between baseline and final antenatal (-2 weeks) NPRS 
score for the DEFO approached clinical significance (0.94), but not 
for the Serola group (0.64).
Secondary outcome Measures
EuroQOL 5 Dimension, 5 Level: (EQ5D-5L)
There were no significant differences between the groups at all 
time intervals either in the ante-natal or post-partum periods for the 
EQ5D-L health state scores (p> 0.05).
EuroQOL 5 Dimension, 5 Level – Visual Analogue Scale (EQ5D-
5L-VAS)
There was a significant effect of Time F(2, 140) = 5.999, p <.001,for 
the antenatal data with health scores increasing over time, but there 
was no significant differences between Groups, F(1, 70) = 1.667, 
p = .264, indicating similar perceived health ratings for both the 
DEFO and SEROLA groups. Pair wise comparisons revealed no 
significant differences between the groups at any time point (all p’s 
>.05). However, there was a significant increase in reported health 
score for the SEROLA group from the first (-6) to final (-2) antenatal 
time points (p <.01); the increase for the DEFO group was close to 
significance (p = .051).
Postnatal results revealed a significant main effect of Time F(2, 
140) = 9.506, p =.001, but no significant differences between 
Groups F(1,70) = 0.092, p = .763. Pair wise comparisons revealed 
no significant differences between the groups at any time point 
(all p’s >.05), but a significant increase in health score for both the 
DEFO (p <.01) and SEROLA (p =.001) groups from the first (+2) 
to final (+6) postnatal score.
Pelvic Girdle Questionnaire (PGQ):
There were no significant differences between the Groups at any 
time intervals either in the antenatal or postpartum periods (p>.05), 
indicating that both groups reported similar levels of activity levels 
and pain across time.
 
Short Form-36, Version 2 (SF-36v2):
Analysis of the SF-36 Physical Component revealed no significant 
difference between the SEROLA and DEFO at all time intervals 
(p >.05). However, the Mental Component revealed significant 
differences between the SEROLA and DEFO at all postnatal time 
intervals (p<.008), and at the final antenatal time interval (p = .008), 
with higher median values for the DEFO than the SEROLA across 
all cases. However, no significant differences were found at either 
the first (p = .110) or second (p = .062) antenatal time intervals.
Follow up analyses using the Friedman’s Test was performed on the 
SF-36 Physical Component to compare differences across all time 
intervals. Results for the SEROLA revealed an overall significant 
difference between time intervals χ2(6) = 142.401, p < 0.001. This 
was also found for the DEFO χ2(6) = 117.221, p < 0.001. Each 
time interval was further analysed using a post hoc Wilcoxon’s 
signed ranks test to determine whether there was any significant 
difference between each linear time interval. Results, which were 
corrected using the Bonferroni adjustment, revealed no significant 
differences for the SEROLA from baseline to the first antenatal 
time interval (-6) (p = .140) or between the first (-6) and second (-4) 
antenatal time interval (p = .647). However, there was a significant 
decline from the second (- 4) and final antenatal time interval (-2) 
(p = .001), but as expected, there was a significant improvement 
from the final antenatal (-2) to first postnatal (+2) and all other 
time intervals (p <.001). Post hoc analysis for the DEFO revealed a 
significant decline from baseline to the first antenatal time interval 
(-6), but this appeared to stabilize during antenatal time period as 
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no significant differences were found between the first (-6) and 
second antenatal (-4) time (p = .694), or second (-4) and last (-2) 
antenatal time interval (p = .728). As expected, there was a significant 
improvement from the last antenatal (-2) to first postnatal (+2) time 
interval and the second postnatal (+4) to last postnatal (+6) time 
interval (p<.001). Finally, the first (+2) to second (+4) postnatal time 
intervals approached significance, following Bonferroni correction
(p = 0.01).
Analysis of the SF-36 Mental Component revealed similar results, 
with a significant difference found for both the SEROLA χ2(6) = 
60.440, p < 0.001 and DEFO χ2(6) = 69.416, p < 0.001 across time. 
Post hoc analysis revealed no significant difference between baseline, 
or any antenatal time intervals (p>.008). However, as expected, a 
significant improvement was found from the last antenatal (-2) to 
first postnatal (+2) time (p<.001), and the first (+2) and second (+4) 
postnatal time (p<.001). No significant difference was also found 
for the second (+4) and final postnatal (+6) time, once corrected 
(p = .025). Post hoc analysis of the DEFO revealed no significant 
differences between the antenatal or postnatal time points (p>.008), 
but as expected a significant difference was found from the last 
antenatal (-2) to first postnatal (+2) time (p<.001). Finally, the 
improvement from baseline to the first antenatal (-6) time interval 
was marginally significant (p = .009).
Discussion
This is the first double blinded, randomised comparative trial 
evaluating the effectiveness of two pelvic orthoses during pregnancy. 
Further it includes the evaluation of a novel intervention, the 
customised DEFO. It shows that, in comparison to the ‘off the 
shelf’ rigid pelvic belt (Serola Belt) group, pain levels for those 
wearing the customised DEFO were significantly less during both 
the day and night. These changes in day time pain were clinically 
significant, as determined by a one point reduction in the NPRS, 
which equates to a ‘slightly better’ improvement in pain. Whilst no 
significant difference was detected between the two groups with 
regard to the secondary outcomes of activity levels and quality 
of life, it is highlighted that the study was not powered to detect 
changes in these outcomes. Further studies could address this issue.
Lee & Vleeming (1998) report the need for force-form closure, 
neuromuscular control and emotion/awareness for optimum joint 
function and a balance between movement and control for optimal 
stability [32]. During pregnancy multiple factors have been shown 
to affect these aspects and potentially contribute to PGP. 
The hormone serum relax in is believed to directly impact ligament 
laxity, thus reducing stability and stiffness in the pelvic girdle [33].
This reduction in stability can lead to increased shear forces through 
the Symphysis Pubis (SP) and SIJ potentially causing pain [2]. The 
European Guidelines for Management and Diagnosis of PGP, along 
with a systematic review completed by Aldabe 2012, reported that
there was a low association between relaxin levels and pregnancy 
related PGP, therefore no conclusion could be drawn [3,33].
Biomechanical changes occur in the lumbar spine and pelvis during 
pregnancy due to the need to adapt centre of gravity as a result of the 
increasing weight of the womb [34]. The increase in maternal weight 
is believed to play a role in the requirement for changing lumbar
biomechanics, with increased lordotic adjustment in the lumbar 
spine required to maintain the centre of gravity [35,36]. Other 
changes such as reduced muscular activity and compensatory muscle 
patterns can also be a potential cause of pain through reduction of 
joint proprioception and neuromuscular control [12].
Pelvic belts are hypothesised to enhance ‘force closure’, thereby 
aiding stability of the pelvic ring and reducing shearing forces through 
the SP and SIJ [11,37-39]. Applying external pelvic compression can: 
be a substitute for normal isometric abdominal activity; increase hip 
adduction strength; and reduce SIJ laxity [11,37-38]. This can also 
lead to a decrease in compensatory mechanisms through the pelvis 
and lumbar spine and facilitate load transfer more appropriately 
[12]. A pelvic belt has been observed to influence proprioception and
neuro-motor control, which can also contribute with the reduction of 
compensatory patterns, and further improving force closure [11,39-
43]. With changing pelvic biomechanics, it has been observed that a 
pelvic orthosis can release strain on sacroiliac ligaments which can
reduce potential tensile stress thus reducing the pain [34,42,43]. 
Passive force-closure using a pelvic belt reduces abdominal muscle 
activation and there are concerns this could lead to muscle weakness 
[9]. The European Guideline advocates that pelvic belts should be
considered alongside other treatment modalities [3]; our study 
supplemented its use with standardised advice.
Strength and limitations of the study
Our study is the first to compare the relative effectiveness of two 
orthoses (plus standardised advice) on pain, activity levels and quality 
of life, providing clinicians and patients with evidence on which to 
guide treatment selection. Self-report questionnaires were used in this 
study, primarily to reduce participant burden and missing data in a 
sample who may find it difficult to attend follow-up assessments due to 
work and family commitments and in whom travelling can irritate their 
pain. This approach, alongside our data checking and management 
systems, are strengths of this study since there was no missing data. 
This is important since missing data can compromise inferences made 
from clinical trials [44]. A particular challenge in this trial was that a 
pre-defined threshold of pain needed to be reached before participants 
were eligible for entry, resulting in participants entering the study 
at different time points during their pregnancy (relative to delivery 
date). The minimisation procedure utilised to reduce the likelihood of 
disparity between the groups, with no significant difference between 
the two groups in their baseline level of pain and the time they entered 
the study. The analyses thereby focused on the final three data points 
in the antenatal phase and the first three data points in the post-partum 
phase – a total of 12 weeks. Future studies could explore whether a 
DEFO could be used at an earlier stage in those individuals at high 
risk of developing PGP since with many musculoskeletal conditions 
prevention/early intervention is favoured.
Conclusion
The novel, customised dynamic elastomeric fabric orthoses was 
more effective than an off-the-shelf rigid pelvic belt at reducing 
day and night time pain in pregnant women with pelvic girdle pain.
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